Skip to main content
. 2017 Mar 1;2(1):2381468317697002. doi: 10.1177/2381468317697002

Table 1.

IPV oSIA Strategies Considered in the Context of a Hypothetical cVDPV2 Outbreak in Northwest Nigeria

IPV oSIA Strategy Short Name Target Population Age Range in Years Vaccine, by oSIA Round
oSIA1 oSIA2 oSIA3 oSIA4 oSIA5
No IPV Outbreak subpopulation 0–4 mOPV2 mOPV2 mOPV2 mOPV2 mOPV2
General population 0–4 mOPV2 mOPV2 mOPV2 mOPV2
No IPV but expand oSIA2 through age 9 Outbreak subpopulation 0–4 mOPV2 mOPV2 mOPV2 mOPV2 mOPV2
5–9 mOPV2
General population 0–4 mOPV2 mOPV2 mOPV2 mOPV2
5–9 mOPV2
No IPV but expand oSIA2 through age 14 Outbreak subpopulation 0–4 mOPV2 mOPV2 mOPV2 mOPV2 mOPV2
5–14 mOPV2
General population 0–4 mOPV2 mOPV2 mOPV2 mOPV2
5–14 mOPV2
IPV added during oSIA1 Outbreak subpopulation 0–4a mOPV2 + IPV mOPV2 mOPV2 mOPV2 mOPV2
General population 0–4 mOPV2 mOPV2 mOPV2 mOPV2
IPV added during oSIA2 Outbreak subpopulation 0–4a mOPV2 mOPV2 + IPV mOPV2 mOPV2 mOPV2
General population 0–4a mOPV2 + IPV mOPV2 mOPV2 mOPV2
IPV added during oSIA5 Outbreak subpopulation 0–4a mOPV2 mOPV2 mOPV2 mOPV2 mOPV2 + IPV
General population 0–4a mOPV2 mOPV2 mOPV2 mOPV2 + IPV
IPV added during all oSIAs Outbreak subpopulation 0–4a mOPV2 + IPV mOPV2 + IPV mOPV2 + IPV mOPV2 + IPV mOPV2 + IPV
General population 0–4a mOPV2 + IPV mOPV2 + IPV mOPV2 + IPV mOPV2 + IPV
IPV 5–9 during oSIA2 Outbreak subpopulation 0–4a mOPV2 mOPV2 mOPV2 mOPV2 mOPV2
5–9 IPV
General population 0–4 mOPV2 mOPV2 mOPV2 mOPV2
5–9 IPV
IPV 5–14 during oSIA2 Outbreak subpopulation 0–4 mOPV2 mOPV2 mOPV2 mOPV2 mOPV2
5–14 IPV
General population 0–4 mOPV2 mOPV2 mOPV2 mOPV2
5–14 IPV
IPV in general during oSIA1 Outbreak subpopulation 0–4 mOPV2 mOPV2 mOPV2 mOPV2 mOPV2
General population 0–4a IPV mOPV2 mOPV2 mOPV2 mOPV2
IPV-only in general during oSIA2 Outbreak subpopulation 0–4 mOPV2 mOPV2 mOPV2 mOPV2 mOPV2
General population 0–4a IPV mOPV2 mOPV2 mOPV2

Note: IPV = inactivated poliovirus vaccine; oSIA = outbreak response supplemental immunization activity; cVDPV2 = serotype 2 circulating vaccine-derived poliovirus; mOPV2 = serotype 2 monovalent oral poliovirus vaccine.

a.

IPV target age range excludes age group from 0 through 2 months.